CN102123711A - 肺动脉高压的治疗 - Google Patents

肺动脉高压的治疗 Download PDF

Info

Publication number
CN102123711A
CN102123711A CN2009801314677A CN200980131467A CN102123711A CN 102123711 A CN102123711 A CN 102123711A CN 2009801314677 A CN2009801314677 A CN 2009801314677A CN 200980131467 A CN200980131467 A CN 200980131467A CN 102123711 A CN102123711 A CN 102123711A
Authority
CN
China
Prior art keywords
lower alkyl
mono
phenyl
amino
pulmonary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801314677A
Other languages
English (en)
Chinese (zh)
Inventor
S·帕斯科
D·奎因
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41137217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102123711(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102123711A publication Critical patent/CN102123711A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2009801314677A 2008-08-13 2009-08-11 肺动脉高压的治疗 Pending CN102123711A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8838208P 2008-08-13 2008-08-13
US61/088,382 2008-08-13
US16450109P 2009-03-30 2009-03-30
US61/164,501 2009-03-30
PCT/US2009/053358 WO2010019540A1 (en) 2008-08-13 2009-08-11 Treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
CN102123711A true CN102123711A (zh) 2011-07-13

Family

ID=41137217

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801314677A Pending CN102123711A (zh) 2008-08-13 2009-08-11 肺动脉高压的治疗

Country Status (16)

Country Link
US (1) US20110190313A1 (OSRAM)
EP (1) EP2315592A1 (OSRAM)
JP (1) JP2011530607A (OSRAM)
KR (1) KR20110053354A (OSRAM)
CN (1) CN102123711A (OSRAM)
AU (1) AU2009282104A1 (OSRAM)
BR (1) BRPI0917491A2 (OSRAM)
CA (1) CA2732789A1 (OSRAM)
CL (1) CL2011000295A1 (OSRAM)
IL (1) IL210922A0 (OSRAM)
MA (1) MA32617B1 (OSRAM)
MX (1) MX2011001668A (OSRAM)
NZ (1) NZ590839A (OSRAM)
RU (1) RU2011109078A (OSRAM)
TW (1) TW201010999A (OSRAM)
WO (1) WO2010019540A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2671029A1 (en) 2009-06-30 2010-12-30 James S. Baldassarre Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
CN109568319A (zh) 2013-01-10 2019-04-05 普尔莫凯恩股份有限公司 非选择性激酶抑制剂
JP6799201B2 (ja) * 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
JP6483714B2 (ja) 2013-10-11 2019-03-13 ローレンス エス． ジスマン， 噴霧乾燥製剤
JP2020500183A (ja) 2016-10-27 2020-01-09 プルモキネ、インコーポレイテッド 肺高血圧症の治療のための併用療法
US10953020B2 (en) 2016-11-08 2021-03-23 Reata Pharmaceuticals, Inc. Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
US20210038510A1 (en) * 2018-02-08 2021-02-11 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US20200360279A1 (en) 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Nebulized imatinib formulations, manufacture, and uses thereof
WO2021108303A1 (en) * 2019-11-25 2021-06-03 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
EP4210684A4 (en) * 2020-09-11 2024-10-09 Pulmosim Therapeutics LLC Compositions and methods for treating or preventing pulmonary hypertension
CA3199324A1 (en) 2020-11-17 2022-05-27 Adam Marc Silverstein Inhaled imatinib for pulmonary hypertension field

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003272007A1 (en) * 2002-10-25 2004-05-13 The Administrators Of The Tulane Educational Fund Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
BRPI0606872A2 (pt) * 2005-01-28 2009-07-21 Novartis Ag uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação de atividade de tie-2 quinase
MX2007013738A (es) * 2005-05-02 2008-01-24 Novartis Ag Derivados de pirimidilaminobenzamida para sindrome hipereosinofilico.
EP1959957B1 (en) * 2005-12-06 2012-07-18 Novartis AG Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
RU2009120882A (ru) * 2006-11-03 2010-12-10 Айрм Ллк (Bm) Соединения и композиции, как ингибиторы протеинкиназы

Also Published As

Publication number Publication date
RU2011109078A (ru) 2012-09-20
KR20110053354A (ko) 2011-05-20
MA32617B1 (fr) 2011-09-01
CL2011000295A1 (es) 2011-07-15
BRPI0917491A2 (pt) 2015-12-01
TW201010999A (en) 2010-03-16
WO2010019540A1 (en) 2010-02-18
US20110190313A1 (en) 2011-08-04
MX2011001668A (es) 2011-03-25
NZ590839A (en) 2013-02-22
AU2009282104A1 (en) 2010-02-18
CA2732789A1 (en) 2010-02-18
IL210922A0 (en) 2011-04-28
JP2011530607A (ja) 2011-12-22
EP2315592A1 (en) 2011-05-04

Similar Documents

Publication Publication Date Title
CN102123711A (zh) 肺动脉高压的治疗
CN102612368B (zh) 治疗增殖性障碍和其它由bcr-abl、c-kit、ddr1、ddr2或pdgf-r激酶活性介导的病理学病症的方法
JP5948246B2 (ja) Ｂｃｒ−ａｂｌ、ｃ−ｋｉｔ、ｄｄｒ１、ｄｄｒ２またはｐｄｇｆ−ｒのキナーゼ活性によって仲介される増殖性障害およびその他の病態の治療方法
US20130040972A1 (en) USE OF c-Src INHIBITORS IN COMBINATION WITH A PYRIMIDYLAMINOBENZAMIDE COMPOUND FOR THE TREATMENT OF LEUKEMIA
US8604045B2 (en) Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis
US20130267549A1 (en) Use of Pyrimidylaminobenzamide Derivatives for the Treatment of Fibrosis
JP2009532440A (ja) ａ）ピリミジルアミノベンズアミド化合物、およびｂ）Ｔｈｒ３１５Ｉｌｅキナーゼ阻害剤を含む、組合せ剤
JP2008540358A (ja) 好酸球増加症候群のためのピリミジルアミノベンズアミド誘導体
EP2186514B1 (en) Treatment of Malignant Peripheral Nerve Sheath Tumors
AU2011202950B2 (en) Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
AU2013201915A1 (en) Use of c-Src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110713